Cellectis
Cellectis is a biotechnology company specializing in the development of gene editing technologies. Founded in 1999, Cellectis is headquartered in Paris, France, with additional offices in the United States. The company is known for its pioneering work in the field of genome engineering, particularly using TALEN and CRISPR technologies.
History[edit]
Cellectis was founded by Dr. André Choulika, a prominent figure in the field of genome editing. The company initially focused on the development of meganucleases for gene editing. Over the years, Cellectis expanded its technology portfolio to include TALEN and CRISPR systems, which have become the cornerstone of its research and development efforts.
Technology[edit]
Cellectis utilizes several advanced gene-editing technologies:
- Meganucleases: These are endonucleases that recognize and cut specific DNA sequences, allowing for precise gene editing.
- TALEN: Transcription Activator-Like Effector Nucleases are engineered proteins that can be designed to target specific DNA sequences for editing.
- CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats is a revolutionary gene-editing technology that allows for highly specific and efficient modification of DNA.
Applications[edit]
Cellectis' technologies have a wide range of applications, including:
- Immunotherapy: Developing CAR-T cell therapy for the treatment of various cancers.
- Agriculture: Enhancing crop traits such as yield, disease resistance, and stress tolerance.
- Gene therapy: Treating genetic disorders by correcting defective genes.
Collaborations and Partnerships[edit]
Cellectis has established numerous collaborations and partnerships with leading pharmaceutical and biotechnology companies. These partnerships aim to leverage Cellectis' gene-editing technologies for the development of novel therapies and products.
Research and Development[edit]
Cellectis is actively involved in research and development to advance its gene-editing platforms. The company has several ongoing clinical trials to evaluate the safety and efficacy of its CAR-T cell therapies in treating various types of cancer.
See also[edit]
References[edit]
External links[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
